Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

Bloomberg Customers


February 09, 2016 1:20 AM ET

Biotechnology

Company Overview of Samumed, LLC

Company Overview

Samumed, LLC is engaged in small molecule drug development using assays and screens for the treatment of oncology and degenerative diseases. Samumed, LLC was known as Wintherix & Epitherix, LLC. The company was founded in 2007 and is based in San Diego, California.

9381 Judicial Drive

Suite 160

San Diego, CA 92121

United States

Founded in 2007

Phone:

858-926-2900

Fax:

858-552-9315

Key Executives for Samumed, LLC

Co-Founder and Chief Executive Officer
Co-Founder and Advisor
Co-Founder and Advisor
Age: 65
Co-Founder and Advisor
Co-Founder and Advisor
Age: 68
Compensation as of Fiscal Year 2015.

Samumed, LLC Key Developments

Samumed Announces Increases in Both Hair Count and Hair Density Observed in its Phase II Study for a Potential Treatment of Androgenetic Alopecia

Samumed, LLC announced preliminary analysis of efficacy data from its Phase II AGA trial, in which one of the dosage arms, compared to vehicle, showed statistically significant increases for both objective outcome measures: non-vellus hair count (a primary outcome measures) and hair density (a secondary outcome measures), using the pre-specified statistical model. Samumed’s investigational drug is a topical solution of its novel small molecule compound SM04554. The 300-subject, multi-center, randomized (1:1:1), double-blind, vehicle-controlled trial studied the safety, tolerability and efficacy of two different doses of SM04554 in male subjects with AGA between the ages of 18 and 55 with Norwood-Hamilton hair loss classification scales of 4, 5, 5A, 5V, or 6. The study involved a 90-day once-a-day treatment period and a 45-day post-treatment follow up. The primary endpoints were the objective quantification by macrophotography of non-vellus hair count, and the subjective assessment of hair quality by subject-completed Men’s Hair Growth Questionnaire. The findings are consistent with preclinical in vivo animal models, in which SM04554 has been shown to generate new hair follicles and increase hair count. The safety results from its Phase II study, as well as results from a previously completed Phase I study, were presented at the 9thWorld Congress for Hair Research (WCHR) in Miami, Florida on November 21, 2015. As the company previously announced, in the Phase II study, there were no serious adverse events observed in any treated patient, and the incidence of adverse events was similar between treatment and vehicle groups.

Samumed, LLC to Announce Clinical Data on Potential Treatment of Androgenetic Alopecia at the World Congress for Hair Research

Samumed, LLC announced that it will present clinical data on a small molecule (SM04554, an investigational new drug) for potential treatment of androgenetic alopecia (AGA), commonly known as male pattern baldness, at the 9thWorld Congress for Hair Research (WCHR) in Miami, Florida. The company is a Silver Sponsor of the meeting. In preclinical in vivo studies, SM04554 has been shown to regenerate new hair follicles and increase hair count in multiple animal models. The company has finished a Phase I trial and is about to complete its Phase II trial with the same potential AGA treatment. At the WCHR, Samumed will present clinical results detailing safety, pK, and patient and investigator-reported efficacy data from a 28-day (14 day dosing, 14 days of follow-up), placebo-controlled, double-blind, randomized Phase I clinical trial of SM04554 in male AGA patients between the ages of 18 and 60 with Norwood-Hamilton Classification scores of 4, 5, 6, or 7.

Similar Private Companies By Industry

Company Name Region
PharmaNutrients, Inc., CLA One Business United States
APT Therapeutics, Inc. United States
Imutran United States
Algisys, LLC United States
LaserGen, Inc. United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Samumed, LLC, please visit www.samumed.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.